Balixafortide (TFA)

• UNSPSC Description:

  Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s [1][2].

• Target Antigen:

  Arrestin; CXCR

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/balixafortide-tfa.html

• Purity:

  99.78

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C(F)(F)F)O.O=C1[C@]2([H])N(CCC2)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@]3([H])NC([C@@H](NC([C@@H](NC([C@@H](NC([C@]4([H])N(CCC4)C([C@@H](NC([C@@H](NC([C@@](CSSC3)([H])NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@]5([H])N1CCC5)=O)CC6=CC=C(C=C6)O)=O)CC7=CN=CN7)=O)C)=O)=O)CO)=O)C)=O)=O)CCN)=O)CCCNC(N)=N)=O)CC8=CC=C(C=C8)O)=O)=O)CC9=CC=C(C=C9)O)=O)CCC(N)=O)=O)CCCCN)=O

• Molecular Weight:

  1978.16

• References & Citations:

  [1]Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.|[2]Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15(1):2.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  Phase 3